1-Methyl-L-tryptophan promotes the apoptosis of hepatic stellate cells arrested by interferon-γ by increasing the expression of IFN-γRβ, IRF-1 and FAS

  • Authors:
    • Ji Eun Oh
    • Kwang Yong Shim
    • Jong In Lee
    • Soo In Choi
    • Soon Koo Baik
    • Young Woo Eom
  • View Affiliations

  • Published online on: June 26, 2017     https://doi.org/10.3892/ijmm.2017.3043
  • Pages: 576-582
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Liver fibrosis, a precursor to cirrhosis, is the result of the deposition of extracellular matrix (ECM) proteins and is mediated primarily by activated hepatic stellate cells (HSCs). In this study, we investigated the anti-fibrotic effects of interferon (IFN)-γ in activated HSCs in vitro and whether cell viability would be decreased by the inhibition of indoleamine 2,3-dioxygemase (IDO), which is responsible for cell cycle arrest. Following treatment with IFN-γ, cell signaling pathways and DNA content were analyzed to assess the inactivation of HSCs or the decrease in HSC proliferation. The IDO inhibitor, 1-methyl-L-tryptophan (1-MT), was used to determine whether IDO plays a key role in the regulation of activated HSCs, as IFN-γ increases the expression of IDO. IFN-γ significantly inhibited the growth of HSCs and downregulated the expression of α-smooth muscle actin (α-SMA) in the HSCs. IDO expression was markedly increased by IFN-γ through signal transducer and activator of transcription 1 (STAT1) activation and resulted in the depletion of tryptophan. This depletion induced G1 cell cycle arrest. When the cells were released from IFN-γ-mediated G1 cell cycle arrest by treatment with 1-MT, the apoptosis of the HSCs was markedly increased through the induction of IFN-γRβ, interferon regulatory factor (IRF-1) and FAS. Our results thus suggest that the inhibition of IDO enhances the suppression of activated HSCs, and therefore co-treatment with IFN-γ and 1-MT may be applied to ameliorate liver fibrosis.

References

1 

Friedman SL: Hepatic fibrosis - overview. Toxicology. 254:120–129. 2008. View Article : Google Scholar : PubMed/NCBI

2 

Kim G, Cho YZ and Baik SK: Assessment for risk of bias in systematic reviews and meta-analyses in the field of hepatology. Gut Liver. 9:701–706. 2015. View Article : Google Scholar : PubMed/NCBI

3 

Kim G, Cho YZ, Baik SK, Kim MY, Hong WK and Kwon SO: The accuracy of ultrasonography for the evaluation of portal hypertension in patients with cirrhosis: A systematic review. Korean J Radiol. 16:314–324. 2015. View Article : Google Scholar : PubMed/NCBI

4 

Eom YW, Shim KY and Baik SK: Mesenchymal stem cell therapy for liver fibrosis. Korean J Intern Med. 30:580–589. 2015. View Article : Google Scholar : PubMed/NCBI

5 

Jang YO, Jun BG, Baik SK, Kim MY and Kwon SO: Inhibition of hepatic stellate cells by bone marrow-derived mesenchymal stem cells in hepatic fibrosis. Clin Mol Hepatol. 21:141–149. 2015. View Article : Google Scholar : PubMed/NCBI

6 

Kim G, Eom YW, Baik SK, Shin Y, Lim YL, Kim MY, Kwon SO and Chang SJ: Therapeutic effects of mesenchymal stem cells for patients with chronic liver diseases: Systematic Review and Meta-analysis. J Korean Med Sci. 30:1405–1415. 2015. View Article : Google Scholar : PubMed/NCBI

7 

Friedman SL: Stellate cells: A moving target in hepatic fibro-genesis. Hepatology. 40:1041–1043. 2004. View Article : Google Scholar : PubMed/NCBI

8 

Friedman SL: Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 88:125–172. 2008. View Article : Google Scholar : PubMed/NCBI

9 

Jang YO, Kim YJ, Baik SK, Kim MY, Eom YW, Cho MY, Park HJ, Park SY, Kim BR, Kim JW, et al: Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: A pilot study. Liver Int. 34:33–41. 2014. View Article : Google Scholar

10 

Bonnem EM and Oldham RK: Gamma-interferon: Physiology and speculation on its role in medicine. J Biol Response Mod. 6:275–301. 1987.PubMed/NCBI

11 

Bouros D, Antoniou KM, Tzouvelekis A and Siafakas NM: Interferon-gamma 1b for the treatment of idiopathic pulmonary fibrosis. Expert Opin Biol Ther. 6:1051–1060. 2006. View Article : Google Scholar : PubMed/NCBI

12 

King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, et al INSPIRE Study Group: Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): A multicentre, randomised, placebo-controlled trial. Lancet. 374:222–228. 2009. View Article : Google Scholar : PubMed/NCBI

13 

Weng HL, Wang BE, Jia JD, Wu WF, Xian JZ, Mertens PR, Cai WM and Dooley S: Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: A randomized controlled study. Clin Gastroenterol Hepatol. 3:819–828. 2005. View Article : Google Scholar : PubMed/NCBI

14 

Ulloa L, Doody J and Massagué J: Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature. 397:710–713. 1999. View Article : Google Scholar : PubMed/NCBI

15 

Ghosh AK, Yuan W, Mori Y, Chen SJ and Varga J: Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators. J Biol Chem. 276:11041–11048. 2001. View Article : Google Scholar : PubMed/NCBI

16 

Higashi K, Inagaki Y, Fujimori K, Nakao A, Kaneko H and Nakatsuka I: Interferon-gamma interferes with transforming growth factor-beta signaling through direct interaction of YB-1 with Smad3. J Biol Chem. 278:43470–43479. 2003. View Article : Google Scholar : PubMed/NCBI

17 

Gu L, Zhu YJ, Guo ZJ, Xu XX and Xu WB: Effect of IFN-gamma and dexamethasone on TGF-beta1-induced human fetal lung fibroblast-myofibroblast differentiation. Acta Pharmacol Sin. 25:1479–1488. 2004.PubMed/NCBI

18 

Poosti F, Bansal R, Yazdani S, Prakash J, Post E, Klok P, van den Born J, de Borst MH, van Goor H, Poelstra K, et al: Selective delivery of IFN-γ to renal interstitial myofibroblasts: A novel strategy for the treatment of renal fibrosis. FASEB J. 29:1029–1042. 2015. View Article : Google Scholar

19 

Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z and Gao B: Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology. 130:435–452. 2006. View Article : Google Scholar : PubMed/NCBI

20 

Melhem A, Muhanna N, Bishara A, Alvarez CE, Ilan Y, Bishara T, Horani A, Nassar M, Friedman SL and Safadi R: Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol. 45:60–71. 2006. View Article : Google Scholar : PubMed/NCBI

21 

Shimizu T, Nomiyama S, Hirata F and Hayaishi O: Indoleamine 2,3-dioxygenase. Purification and some properties. J Biol Chem. 253:4700–4706. 1978.PubMed/NCBI

22 

Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R and Muller AJ: Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother. 63:721–735. 2014. View Article : Google Scholar : PubMed/NCBI

23 

Munn DH and Mellor AL: Indoleamine 2,3-dioxygenase and tumor induced tolerance. J Clin Invest. 117:1147–1154. 2007. View Article : Google Scholar : PubMed/NCBI

24 

Liebau C, Baltzer AW, Schmidt S, Roesel C, Karreman C, Prisack JB, Bojar H and Merk H: Interleukin-12 and interleukin-18 induce indoleamine 2,3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma. Anticancer Res. 22:931–936. 2002.PubMed/NCBI

25 

Fujigaki S, Saito K, Sekikawa K, Tone S, Takikawa O, Fujii H, Wada H, Noma A and Seishima M: Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Eur J Immunol. 31:2313–2318. 2001. View Article : Google Scholar : PubMed/NCBI

26 

Carlin JM, Ozaki Y, Byrne GI, Brown RR and Borden EC: Interferons and indoleamine 2,3-dioxygenase: Role in antimicrobial and antitumor effects. Experientia. 45:535–541. 1989. View Article : Google Scholar : PubMed/NCBI

27 

Mallat A, Preaux AM, Blazejewski S, Rosenbaum J, Dhumeaux D and Mavier P: Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology. 21:1003–1010. 1995. View Article : Google Scholar : PubMed/NCBI

28 

Fort J, Pilette C, Veal N, Oberti F, Gallois Y, Douay O, Rosenbaum J and Calès P: Effects of long-term administration of interferon alpha in two models of liver fibrosis in rats. J Hepatol. 29:263–270. 1998. View Article : Google Scholar : PubMed/NCBI

29 

Inagaki Y, Nemoto T, Kushida M, Sheng Y, Higashi K, Ikeda K, Kawada N, Shirasaki F, Takehara K, Sugiyama K, et al: Interferon alfa downregulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology. 38:890–899. 2003. View Article : Google Scholar : PubMed/NCBI

30 

Mailankot M, Smith D, Howell S, Wang B, Jacobberger JW, Stefan T and Nagaraj RH: Cell cycle arrest by kynurenine in lens epithelial cells. Invest Ophthalmol Vis Sci. 49:5466–5475. 2008. View Article : Google Scholar : PubMed/NCBI

31 

Croitoru-Lamoury J, Lamoury FM, Caristo M, Suzuki K, Walker D, Takikawa O, Taylor R and Brew BJ: Interferon-γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO). PLoS One. 6:e146982011. View Article : Google Scholar

32 

Baroni GS, D'Ambrosio L, Curto P, Casini A, Mancini R, Jezequel AM and Benedetti A: Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology. 23:1189–1199. 1996. View Article : Google Scholar : PubMed/NCBI

33 

Muir AJ, Sylvestre PB and Rockey DC: Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. J Viral Hepat. 13:322–328. 2006. View Article : Google Scholar : PubMed/NCBI

34 

Rutenfranz I and Kirchner H: Pharmacokinetics of recombinant murine interferon-gamma in mice. J Interferon Res. 8:573–580. 1988. View Article : Google Scholar : PubMed/NCBI

35 

Kano A, Watanabe Y, Takeda N, Aizawa S and Akaike T: Analysis of IFN-gamma-induced cell cycle arrest and cell death in hepatocytes. J Biochem. 121:677–683. 1997. View Article : Google Scholar : PubMed/NCBI

36 

Li F, Li QH, Wang JY, Zhan CY, Xie C and Lu WY: Effects of interferon-gamma liposomes targeted to platelet-derived growth factor receptor-beta on hepatic fibrosis in rats. J Control Release. 159:261–270. 2012. View Article : Google Scholar : PubMed/NCBI

37 

Bansal R, Prakash J, De Ruiter M and Poelstra K: Interferon gamma peptidomimetic targeted to hepatic stellate cells ameliorates acute and chronic liver fibrosis in vivo. J Control Release. 179:18–24. 2014. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

August 2017
Volume 40 Issue 2

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Oh, J.E., Shim, K.Y., Lee, J.I., Choi, S.I., Baik, S.K., & Eom, Y.W. (2017). 1-Methyl-L-tryptophan promotes the apoptosis of hepatic stellate cells arrested by interferon-γ by increasing the expression of IFN-γRβ, IRF-1 and FAS. International Journal of Molecular Medicine, 40, 576-582. https://doi.org/10.3892/ijmm.2017.3043
MLA
Oh, J. E., Shim, K. Y., Lee, J. I., Choi, S. I., Baik, S. K., Eom, Y. W."1-Methyl-L-tryptophan promotes the apoptosis of hepatic stellate cells arrested by interferon-γ by increasing the expression of IFN-γRβ, IRF-1 and FAS". International Journal of Molecular Medicine 40.2 (2017): 576-582.
Chicago
Oh, J. E., Shim, K. Y., Lee, J. I., Choi, S. I., Baik, S. K., Eom, Y. W."1-Methyl-L-tryptophan promotes the apoptosis of hepatic stellate cells arrested by interferon-γ by increasing the expression of IFN-γRβ, IRF-1 and FAS". International Journal of Molecular Medicine 40, no. 2 (2017): 576-582. https://doi.org/10.3892/ijmm.2017.3043